 |
andexanet alfa |
|---|---|
| Trade Name | |
| Orphan Indication | For reversing the anticoagulant effect of direct or indirect factor Xa inhibitors in patients experiencing a serious uncontrolled bleeding event or who require urgent or emergent surgery |
| USA Market Approval | USA |
| USA Designation Date | 2015-02-23 00:00:00 |
| Sponsor | Portola Pharmaceuticals;270 East Grand Avenue;South San Francisco, California, 94080 |
